Vitamin K2 technology wins award for Nattopharma pharmaceutical spin-off
Kaydence Pharma recognized at the BIO-International Convention
Oslo, Norway and Edison, NJ (17 juLY 2019) — Kaydence Pharma, the pharmaceutical company that spun-off from NattoPharma in 2017, received the Start-Up Stadium Award for Therapeutics at the Biotechnology Innovation Organization (BIO) annual international convention held in June in Philadelphia, PA. BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations, offering Kaydence a strong platform for its exclusive focus on developing menaquinone-7 as a pharmaceutical product for vascular and other tissue calcification-related diseases. The Kaydence entry was based on NattoPharma’s substantial body of scientific evidence and intellectual property (IP).
According to BIO, the goal of Start-up Stadium is to increase start-ups’ engagement and visibility with investors, state and regional affiliates, and early-stage companies. The 2019 event saw the most applications ever submitted (150+), across the largest geographical footprint (24 states, 13 countries), with the most judges ever involved between two rounds (60+ total), BIO reports.
“Vascular calcification is one of the most serious and life-threatening conditions worldwide, impacting millions. It was gratifying to have panel of pharma-industry experts corroborate a compelling investment case for Kaydence Pharma and our important work, which is to develop novel ground-breaking therapies to help patients prevent and reverse vascular calcification with vitamin K2 as menaquinone-7,” says Daniel Rosenbaum, Kaydence Pharma CEO.
Winning companies receive a one-year membership in BIO, a one-hour advisory discussion with two venture capital firms and will be fast-tracked into the final selection phase for up to a $75,000 convertible note as part of the Delaware Innovation Space’s First Fund program.
“NattoPharma is thrilled to see the work we have pioneered since our inception has resulted in the ability to pursue a new drug application in this exciting new venture called Kaydence,” says NattoPharma CEO Kjetil Ramsøy. “As the majority shareholder in Kaydence Pharma, we applaud our colleagues for impressing upon this esteemed audience the importance of their mission and indelible impact vitamin K2 as MK-7 can have on changing the face of global health.”
XXX
About Kaydence Pharma
Kaydence Pharma is an emerging pharmaceutical company focused exclusively on the development of menaquinone-7 as a pharmaceutical product for vascular and other tissue calcification-related disease associated with the loss of arterial flexibility. Spun-off from NattoPharma ASA, a publically traded company (Oslo Børs, Norway) that has led in the clinical validation and commercialization of vitamin K2 for cardiovascular and bone health within the dietary suplement segement, Kaydence Pharma is now an independent, privately-owned company registered in Norway and operating in both Oslo, Norway and New Brunswick, NJ, USA. For more information, visit www.kaydencepharma.com.
About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the supplement industry world leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending; and now the new MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, and 9. The company has a multi-year research and development program to substantiate and discover the health benefits of Vitamin K2 for applications in the marketplace for functional food and dietary supplements, in addition to exclusive access to the research efforts of its pharmaceutical arm, Kaydence Pharma AS (est. 2017), outside of the pharmaceutical domain. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.
For more information, please contact:
Kate Quackenbush, NattoPharma Director of Communications
P: 609-643-0749 x 220; E: kate.quackenbush@nattopharma.com
Tags: